|1.||Romero, Pedro: 31 articles (09/2014 - 03/2002)|
|2.||Speiser, Daniel E: 25 articles (09/2014 - 03/2002)|
|3.||Guillaume, Philippe: 19 articles (06/2012 - 03/2002)|
|4.||Cerottini, Jean-Charles: 19 articles (03/2007 - 03/2002)|
|5.||Rufer, Nathalie: 16 articles (09/2014 - 10/2002)|
|6.||Jotereau, Francine: 15 articles (03/2012 - 09/2002)|
|7.||Rimoldi, Donata: 14 articles (09/2010 - 03/2002)|
|8.||Baumgaertner, Petra: 11 articles (11/2012 - 07/2006)|
|9.||Rivoltini, Licia: 10 articles (01/2015 - 10/2002)|
|10.||Jasiulionis, Miriam G: 10 articles (01/2013 - 04/2005)|
|1.||Melanoma (Melanoma, Malignant)
12/01/2002 - "An antibody panel consisting of Mitf and Melan-A is superior to a panel of S-100 and HMB-45 in the diagnosis of melanoma in cytologic specimens."
08/01/2004 - "Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival."
05/01/2002 - "Melan-A, in particular, may be helpful for the cytological diagnosis of canine melanoma."
10/01/2001 - "While there were no positive results in localized disease (stages I and II), identification of specific PCR products in stage III melanoma patients was restricted to the MART-1/Melan-A tests, with positive results in 11% (two out of 19) of the blood specimens analysed. "
09/01/2013 - "Additional immunohistochemistry studies confirmed immunoreactivity for CD68, CD45, CD45RO, and CD15 and were negative for CD3, CD20, melanoma cocktail, CD30, CD1a, CD34, HMB-45, and melan-A. "
12/01/2013 - "Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials."
11/15/2002 - "In this study, we have analyzed the recognition of sequences retrieved by using a biometric analysis of the data generated by screening a PS-SCL with a tumor-reactive CTL clone specific for an immunodominant peptide from the melanocyte differentiation and tumor-associated Ag Melan-A. "
12/01/2001 - "Immunohistochemical studies showed reactivity to the anti-Melan-A A103 antibody, suggesting an adrenal origin of the tumor cells. "
01/01/2016 - "There is variable positivity for HMB-45, MelanA, MiTF, and CathepsinK, and some tumors have been shown to express TFE-3 especially when associated with "clear cell" morphology. "
11/01/2015 - "The authors therefore performed immunohistochemical analyses of tumor cell proliferation (Melan-A/Ki67) and infiltration of inflammatory cells (CD66b neutrophils and CD163 macrophages) to better understand the biology of the epidermal changes described. "
12/01/2004 - "Melan-A is very useful in distinguishing between DMM and sclerotic nevi. "
02/01/2015 - "Interpretation of nodal nevus staining (negative by HMB-45) was significantly aided by the crisp nuclear staining produced by SOX10 as compared with the obscuring cytoplasmic staining produced by S100 protein and Melan-A in 3 cases. "
02/01/2015 - "SOX10 stained nodal nevi in a similar manner to S100 protein and Melan-A in 4 cases. "
02/01/2012 - "Melan-A immunostains were also used to screen 25 cases of grossly normal fetal skin for occult fetal nevi. "
12/01/2004 - "In contrast, 100% of the 13 nevi were strongly positive for Melan-A (P < 0.001). "
|4.||Pigmented Nevus (Melanocytic Nevus)
10/01/2012 - "melanocytic nevi, because of their histopathologic attributes (symmetric silhouette, benign cytologic features) and results from immunohistochemical studies (all lesions strongly expressed Melan-A and p16) and fluorescence in situ hybridization (FISH). "
07/01/2012 - "Our data indicate that Melan-A immunohistochemical staining is helpful in differentiating neurotized melanocytic nevi from neurofibromas when distinction on histomorphology alone is difficult."
07/01/2012 - "All of the melanocytic nevi showed Melan-A staining within the neurotized areas, with most of the areas staining strongly positive, whereas all the neurofibromas were completely absent of Melan-A stain. "
07/01/2012 - "To determine whether Melan-A (MART-1) immunohistochemical stain is sufficient to differentiate neurotized melanocytic nevi from neurofibromas. "
07/01/2012 - "Differentiating neurotized melanocytic nevi from neurofibromas using Melan-A (MART-1) immunohistochemical stain."
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|1.||Monophenol Monooxygenase (Tyrosinase)
|3.||Messenger RNA (mRNA)
|4.||S100 Proteins (S 100 Protein)
|5.||HLA-A2 Antigen (HLA A2 Antigen)
|3.||Mohs Surgery (Mohs' Micrographic Surgery)
|4.||Lymph Node Excision (Lymph Node Dissection)